New insights into folliculotropic mycosis fungoides (FMF): A single-center experience - 20/07/16
, Iris Amitay-Laish, MD a, d, Lihi Atzmony, MD a, Hadas Prag-Naveh, MD a, Natalia Yanichkin, MD b, Aviv Barzilai, MD c, d, Ruben Kershenovich, MD a, Meora Feinmesser, MD b, dAbstract |
Background |
It is generally accepted that folliculotropic mycosis fungoides (FMF) is usually typified by indurated plaques and tumors mainly on the head/neck and an aggressive course. However, its clinical manifestations have long been recognized to be quite variable, and some studies indicate a better prognosis for certain presentations.
Objective |
We sought to summarize our experience with the clinicopathological presentations of FMF and impact on prognosis.
Methods |
Data were collected retrospectively for adults with FMF followed up prospectively at a tertiary medical center in 1995 through 2014.
Results |
In all, 34 patients presented with follicle-based patch/flat plaques, keratosis pilaris–like lesions, and/or acneiform lesions, defined clinically as early stage (IA, IB), and 15 presented with follicle-based infiltrated plaques and/or tumors, defined as advanced stage (IIB). The head/neck was involved in all tumor-stage cases, whereas early-stage lesions involved mainly the trunk/limbs. The tumor stage was characterized by more pruritus, heavier perifollicular infiltrates, greater vertical depth, and more frequent presence of eosinophils. On multivariate analysis, infiltrate density was the only significant histopathological discriminator between the stages. Estimated 5-year survival was 0.94 in the early-stage group and 0.69 in the tumor-stage group.
Limitations |
Lack of long-term follow-up and relatively small sample are limitations.
Conclusion |
FMF presents with 2 distinct patterns of clinicopathologic features, early stage and advanced stage, each with different prognostic implications.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous T-cell lymphoma, folliculotropic mycosis fungoides, histopathology, mycosis fungoides, prognosis
Abbreviations used : EORTC, FMF, KPLL, MF, WHO
Plan
| Drs Hodak and Amitay-Laish contributed equally to the study. |
|
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 75 - N° 2
P. 347-355 - août 2016 Retour au numéro
Article précédent
- Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis
- Alexander Egeberg, Louise E. Bruun, Lotus Mallbris, Gunnar H. Gislason, Lone Skov, Jashin J. Wu, Peter R. Hansen
- Evaluation of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) classification scheme for diagnosis of cutaneous melanocytic neoplasms: Results from the International Melanoma Pathology Study Group
- Jason P. Lott, Joann G. Elmore, Ge A. Zhao, Stevan R. Knezevich, Paul D. Frederick, Lisa M. Reisch, Emily Y. Chu, Martin G. Cook, Lyn M. Duncan, Rosalie Elenitsas, Pedram Gerami, Gilles Landman, Lori Lowe, Jane L. Messina, Martin C. Mihm, Joost J. van den Oord, Michael S. Rabkin, Birgitta Schmidt, Christopher R. Shea, Sook Jung Yun, George X. Xu, Michael W. Piepkorn, David E. Elder, Raymond L. Barnhill, International Melanoma Pathology Study Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?